Key result
HCM linked to ~19% lower MAPSE versus healthy controls, indicating impaired LV longitudinal function.
Why the study?
Few studies have compared cardiac magnetic resonance-derived TAPSE and MAPSE measurements between patients with hypertrophic cardiomyopathy and normal controls.
Do CMR-derived MAPSE and TAPSE values differ between patients with hypertrophic cardiomyopathy and normal individuals?
Cross-Sectional (n=70)
No
Do CMR-derived MAPSE and TAPSE values differ between patients with hypertrophic cardiomyopathy and normal individuals?
Absolute Event Rate: 11.7% vs 14.5%
p-value: p=<0.001
CMR-derived MAPSE is significantly reduced in patients with hypertrophic cardiomyopathy compared to healthy controls, indicating impaired left ventricular longitudinal function, whereas right ventricular longitudinal function (TAPSE) appears preserved.
Indicates impaired LV longitudinal function in HCM; leaves open CMR-MAPSE's prognostic utility pending prospective studies.
OBJECTIVE: Hypertrophic cardiomyopathy (HCM) is a genetic disease with an incidence of 0.2%-0.5%. It has a wide range of clinical presentations varying from coincidental diagnoses to heart failure, ventricular arrhythmias and sudden cardiac death. Mitral annular plane systolic excursion (MAPSE) and tricuspid annular plane systolic excursion (TAPSE) are M-mode-derived practical and reproducible measurements of systolic longitudinal displacement of the annular plane. These two measures may be used as markers of the left ventricular and right ventricular longitudinal functions. Currently, there are only a few studies on cardiac magnetic resonance (CMR)-derived TAPSE and MAPSE measurement comparison between the HCM group and normal control group. The aim of our study is to show the differences in CMR-derived TAPSE and MAPSE values between the HCM and normal population. METHODS: We evaluated CMR exams of patients diagnosed with HCM and of normal individuals scanned between 2020 and 2021 retrospectively. The patients were from our own institution's and other hospitals' in- and out-patient departments. Data was collected on 36 HCM patients and 34 adults with no known history of cardiac and non-cardiac diseases. All CMR exams were performed on a 1.5 T (Magnetom Avanto, Siemens Healthcare, Erlangen, Germany) scanner. CMR-derived MAPSE and TAPSE were measured on standard four-chamber steady-state free precession (SSFP) cine images and given in millimeters. RESULTS: From February 2020 to December 2021, a total of 150 patients were diagnosed with hypertrophic cardiomyopathy. After exclusion, 36 patients with HCM were included in the study and the normal control group comprised 34 individuals. The mean age of the HCM group was 43.2 + 13.5 years, while it was 37.5 + 11.3 in the control group. The female ratio of the HCM group was found to be 36%, while it was 56% in the healthy control group. MAPSE values were significantly higher in the normal control group when compared to the HCM patient group (MAPSE: 14.5 ± 2.9 mm vs. 11.7 ± 3.2 mm; p<0.001), while TAPSE values did not depict a significant difference between the two groups (p=0.627). CONCLUSIONS: This study suggests that MAPSE values are significantly lower in the HCM patient group in comparison with the normal control group on CMR scans. Although not statistically significant, TAPSE values are also lower in the HCM group.
No takes yet. Share an insight, caveat, or question.
Tok et al. (2023) conducted a cross-sectional in Hypertrophic Cardiomyopathy (n=70). Hypertrophic Cardiomyopathy vs. Healthy controls was evaluated on CMR-derived MAPSE (mitral annular plane systolic excursion) (p=<0.001). Hypertrophic cardiomyopathy patients had significantly lower CMR-derived MAPSE values compared to healthy controls (11.7 mm vs 14.5 mm, p<0.001), indicating impaired left ventricular longitudinal function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: